AT4 receptors: Specificity and distribution  by Harding, Joseph W. et al.
Kidney International Vol. 46 (1994), pp. 1510—1512
AT4 receptors: Specificity and distribution
JOSEPH W. HARDING, JOHN W. WRIGHT, GEOFFREY N. SWANSON, J0DIE M. HANESWORTH,
and Lun T. KREBS
Department of Veterinaiy and Comparative Anatomy, Pharmacology and Physiology, and Department of Psychology, Washington State University,
Pullman, Washington, USA
AT4 receptor Specificity and distribution. The AT4 receptor specifically
binds Angiotensin (Ang) IV and is distinct from the AT1 and AT2
receptors which bind Ang II and Ang III. The AT4 receptor in bovine
adrenal cortex has a K. of 0.74 0.14 nM and a Bmw. of 3.82 1.12
pmol/mg plot. Competition curves demonstrated the following rank order
of affinity: Ang IV >> Ang III >> d-Arg — Ang II>> Sar', lie8 — AngII = Ang II = Ang 11(1-7) >> DuP753 = CGP42112A = PD 123177.
AT4 receptors were present in many tissues from several mammalian
species including human and monkey. AT4 and AT1/AT2 receptors
revealed a differential distribution in the rat kidney.
The angiotensin family of peptides has long been recognized as
a critical regulator of cardiovascular function and body water
homeostasis. The integrative nature of angiotensin's regulatory
role encompasses a myriad of specific functions, most of which
have been attributed to the action of the octapeptide, angiotensin
II (Ang II) and to a lesser extent the N-terminal deleted hep-
tapeptide, angiotensin III (Ang III) [1]. As such, the majority of
research in the angiotensin field over the last several decades has
focused on Ang II and Ang III, Ang Il/Ang Ill-dependent
physiologies, and Ang Il/Ang III receptors. By comparison, little
work has been carried out on the physiological, biochemical, or
pharmacological properties of smaller angiotensin fragments or
alternatively processed peptides. This is not surprising, given that
smaller fragments neither exhibited Ang Il-like physiological
activity [2] nor bind Ang II receptors with high affinity [3].
Recently however, investigators have begun to examine smaller
fragments like Ang 11(3—8) (most recently called Ang IV) and
Ang 11(1-7) [4], not from the perspective of Ang Il/Ang III
dependent functions, but with the idea that these peptides might
mediate unique roles which are divorced from Ang II's.
Most germane to this report are several recent studies which
have described physiological functions of Ang IV that are distinct
from Ang II's. While Ang II is in general a vasoconstrictor,
decreasing blood flow to tissues, Ang IV appears to increase blood
flow in the cortex of the rat kidney [5], in rabbit brain arterioles
[6], and in rat brain arterioles (Wright and Kramer, personal
communication). In addition, Ang IV has been shown to be an
effective enhancer of cognitive function as assessed in a passive
avoidance paradigm [7, 8], and may possess unique growth
regulatory effects on the heart [9] and on vascular endothelial cells
(Hall, personal communication).
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Implicit in the elucidation that Ang IV elicits unique cellular
and tissue responses is the existence of specific Ang IV receptors.
Furthermore, the cellular location of these receptors should
correspond to the observed physiological response. Several stud-
ies have been reported that do describe the existence of an Ang
IV specific receptor in predicted locations [8, 10—15]. The purpose
of this report is to consolidate and highlight our knowledge
regarding the specificity and distribution characteristics of AT4
receptors.
Methods
Bovine adrenals were obtained from a local slaughterhouse.
The tissue was homogenized in 40 vol. of hypotonic buffer
containing 50 mri Tris, pH 7.4, and 5 mM EDTA, and spun at
1,000 x g for 10 minutes. The supernatant was removed and
re-centrifuged at 40,000 X g for 30 minutes. The pellet was
re-homogenized in hypotonic buffer and re-centrifuged. The
40,000 X g pellet was homogenized in isotonic buffer (50mrt Tris,
pH 7.4, 5 mri EDTA, 150 mivi NaCl, 20 M bestatin, 50 .LM
Plummer's inhibitor, 100 M PMSF, and 0.1% heat-treated BSA)
and re-centrifuged a final time at 40,000 X g. The pellet was
resuspended at a concentration of 2.5 mg protein/ml as deter-
mined by the Lowry protein assay [16]. Binding assays, which
totaled 250 tl, contained 10 i.d '251-labeled Ang IV (sp. act. 2176
Ci/mmol; 0.5 nM), 10 ui tissue homogenate, 10 .d unlabeled
peptide (if employed), and the remainder isotonic buffer. Incuba-
tions were carried out for two hours at 37°C. Preliminary exper-
iments demonstrated that incubation for one hour at 37°C was
necessary for equilibrium to be reached and that binding was
stable for at least four hours. At that time less than 10% of the
[1251] Ang IV was shown to be metabolized by HPLC analysis.
Saturation isotherms were developed using 12 concentrations of
[125!] Ang IV in duplicate, and included total and non-specific
binding (+ 100 flM Ang IV). Competition curves were developed
using 500,000 cpm/tube (0.6 n of [1251] Ang IV and varying
unlabeled peptide (106M —* 10'M) in half-log dilutions (Dup
753, CGP42112A: 104M — 10"M).
Autoradiographic analysis of rat kidney binding was carried out
using 20 .tM tissue sections mounted on subbed slides. Slices were
initially pre-incubated in isotonic buffer for 30 minutes at room
temperature, then incubated in labeled ligand (0.6 nM) for two
hour, rinsed, dried and exposed to X-ray film as previously
described [17].
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Table 1. Competition curves for '251-Sar', Ile5 -Ang II and 125j - Ang
IV binding to bovine adrenal cortical membranes
Competitor 1251-Sar1, He8 (K1, M) 1251-Ang IV
Sar1, Ile5-Ang II
Ang II
Ang III
Ang IV
DuP 753
0.22 10 X iO
2.01 0.67 X iO
1.15 0.34 X 1O
> 10—6
3.10 0.67 x io
> 10—6
> 10—6
14.50 2.3 X 1O
0.58 0.15 X 10
> 1O
CGP42112A > i0 > i0
PD123 177 > i0 > i0
Ang 11(1-7)
d-Arg Ang III
> 10—6
NP
> i0
2.78 0.45 X 1O
Data are mean 5D, N = 4.
a Not tested
Fig. 1. Receptor autoradiography in 20 pm adjacent sections of rat kidney.
Incubations were carried out as described in the text. A. Total 1251-Ang IV
binding; B. 1I-Ang IV binding in the presence of 100 nM Ang IV; C.
'251-Ang IV binding in the presence of 100 nM Sar',Ile8-Ang II; D. Total
1I-Sar,Ile8-Ang II binding; E. '251-Sar',Ilc8-Ang II binding in the
presence of 100 nM Ang IV; F. 1251-Sar1,Ile5-Ang II binding in the
presence of 100 nM Sar1,Ile5-Ang II.
Results
The properties of AT4 recepwrs have been extensively exam-
ined in many tissues in mammalian species and found to be
distinct from AT1/AT2 receptors. To illustrate the typical proper-
ties of AT4 receptors and how they compare to the properties of
AT1 and AT2 receptors, data for bovine adrenals are presented
above.
The first investigation of this new binding site was designed to
unequivocally establish that Sar1, 11e8-Ang II (an AT1/AT2 non-
Table 2. Binding constants for AT4 receptors in various species and
tissues
Bm flnollmg
Species Tissue K.4 riM protein
Rabbit Heart 1.75 5 731 163
Rat Heart 3.3 1.1 320 66
Bovine Adrenals 0,74 0.14 3820 1120
Guinea pig Heart 1.33 0.02 144 19
Guinea pig Hippocampus 1.29 0.18 499 62
Bovine Vascular smooth muscle 1.85 0.45 960 100
Bovine Vascular endothelial cells 0.70 1.0 476 57
Guinea pig Vascular smooth muscle 0.40 0.09 1040 239
Monkey Kidney 1.5 0.31 1000 212
Guinea pig Colon 0.84 0.08 659 75
Human Prostate 0.60 0.15 1399 152
Data are mean sn, N = 2 to 4.
selective ligand) and 'I-Ang IV binding proteins were different.
These studies were carried out using a plasma membrane fraction
from bovine adrenal cortex. Initial kinetic studies determined that
both 1I-Sar1,Ile5-Ang II and 1251-Ang IV binding were charac-
terized by slow on rates and very slow off rates. The kinetically
determined binding constants for both ligands were as follows:
1251-Sar1,Ile8-Ang II (K = 0.23 0.03 nral, N = 3); 125 1-Ang IV(K, = 0.44 0.05 nM, N = 3). Subsequent equilibrium studies
were carried out at 37°C with a 120 minute incubation. Under
these conditions radioligand metabolism was less than 10% as
assessed by HPLC. Nonspecific binding was defined as total
binding minus binding in the presence of 100 nr'n Sar1,11e6-Ang II
or 100 nM Ang IV. No cross displacement was evident. The
saturation isotherms indicated the presence of a single saturable
binding site for each ligand. The equilibrium constants were as
follows: 1I-Sar1,Ile5-Ang II (K = 0.54 0.14 nM, Bma,, = 1.03
0.26 pmollmg prot, N = 4); 1251-Ang IV (K = 0.74 0.14 n,
Bmax = 3.82 1.12 pmol/mg prot, N = 4).
Although large differences in the Bma,, values between the
I-Sar1,Ile5-Ang II and 1251-Ang IV binding suggested that these
ligands bound, at least in part, to separate sites, the distinction
between the sites became clearer in competition studies which
demonstrated radically different structure-binding relationships
for the two binding sites (Table 1). The Sar1,11e5-Ang II site bound
Sar1,Ile8-Ang II, Ang II, Ang III, and DuP753 (AT1 specific) with
high affinity while having little affinity for Ang IV, PD123177 (AT2
specific) and CGP42112A (AT2 specific). This pattern of binding
is consistant with an AT1 site. The Ang IV site bound only Ang IV
and Ang III with high affinity. Despite the apparent ability of Ang
III to bind this site, additional data (not shown) indicated that the
binding attributed to Ang III was actually the result of Ang IV
formed during Ang III degradation. Furthermore, D-Arg-Ang III,
a metabolically resistant form of Mg III, had a significantly lower
apparent binding affinity.
To further illustrate that AT4 and AT1/AT2 receptors are
indeed distinct, the differential distribution of these receptors is
shown in rat kidney (Fig. 1). The left-hand column including
panels A, B, and C shows 1251-Ang IV binding which defines AT4
receptors. Panel A is total 1251-Ang IV binding, panel B is
nonspecific binding in the presence of 100 n Mg IV, and panel
C is cross displacement in the presence of 100 n Sar1,Ile8-Ang II.
The right hand column including panels D, E, and F shows
1251-Sar1,11e5-Ang II binding which defines AT1/AT2 receptors.
Panel D is total 1251-Sar1,11e8-Ang II binding, panel E is cross
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displacement in the presence of 100 nM Ang IV, and panel F is
nonspecific binding in the presence of 100 nM Sar1,11e8-Ang II.
The exclusivity of the receptor types is indicated by the lack of
cross displacement. This is further highlighted by the differential
localization of the receptors with the AT4 receptor concentrated
in the outer stripe of the medulla and the AT1/AT2 receptors
localized in glomeruli and the core of the medulla.
Distribution studies (both species and tissue) play a critical part
in the initial characterization of a new binding site. First, they can
help to ventS' the unique character of a new site, especially in
comparison to receptors with potentially related functions. Sec-
ond, they can serve to establish the universality of the receptor,
implying an important and conserved role. And finally and
perhaps most importantly, the tissue distribution of the receptor
can provide important clues about the function of this receptor
and its accompanying peptide system.
The results of specific distribution studies indicate that Ang IV
binding sites are present in all mammalian species examined.
These include human, monkey, guinea pig, rat, dog, cow, pig,
rabbit, cat, and horse. In addition to being universally present in
mammals, Mg IV receptors are widely distributed in different cell
types and tissues. Examples are shown in Table 2.
Discussion
The results presented demonstrate that AT4 and AT1/AT2
receptors are distinct entities with different ligand specificities and
differential distributions. These differences in specificity and lo-
cation suggest that Mg H and Mg IV may mediate different
physiological responses. This notion is verified in the rat kidney
where Ang II decreases cortical blood flow while Mg IV increases
cortical blood flow [10]. In the brain the localization of AT1
receptors, which are concentrated in regions associated with
cardiovascular control, is consistent with Mg II's known functions
[1] while the localization of AT4 receptors in the pyramidal cell
layer of the hippocampus is consistent with its role in cognition [7,
8].
The identification of AT4 receptors in numerous tissues where
no role for Mg IV has yet been elucidated should serve as a guide
for deciphering these functions. Despite the wide and varied
distribution of AT4 receptors described in this study, the tissues
included only represent a partial list of tissues and cells containing
AT4 receptors. As such it would appear that there are almost
unlimited opportunities to describe previously unrecognized func-
tions for Mg IV.
Reprint requests to Joseph W. Hardin& M.D., Department of VCAPP,
Washington State University, Pullman, Washington 99164-6520, USA.
References
1. WRIGHT JW, HARDING JW: Brain angiotensin receptor subtypes in the
control of physiologicaland behavioral responses. Neurosci Biobehav
Rev 18:21—53, 1994
2. TONNEAR JA, WIEGANT VM, DEJONG W, DEWIED D: Central effects
of angiotcnsins on drinking and blood pressure: Structure-activity
relationships. Brain Res 236:417—428, 1982
3. PENDLETON RG, GE55NER 0, HORNER E: Studies defining minimal
receptor domains for angiotensin II. JPharmacol Exp Ther 250:31—36,
1989
4. FERRARLO CM, BRO5NIHAN KB, DIz DI, TMswAL N, KHO5LA MC,
MIL5TED A, TALLANT EA: Angtiotensin (1-7): A new hormone of the
angiotensin system. Hypertension 18:111-126—111-133, 1991
5. COLEMAN JKM, ONG B, SARDINIA MF, HARDING MW, WRIGHT 3W:
Changes in renal blood flow due to infusions of angiotensin 11(3-8)
[MV] in normotensive rats. (abstract) FASEB J 6:A981, 1992
6. HABERL RL, DEcKER PJ, EINFIAUPL KML: Angiotensin degradation
products mediate endothelium-dependent dilation of rabbit brain
arterioles. Circ Res 68:1621—1627, 1991
7. Blt&szKo 33, WLA5IENKO 3, KuPRYszEwsxl 0, Wrrczuc B,
WIsNIEwsIG K: Behavioral effects of angiotensin II and angiotensin II
(4-8) pentapeptide in rats. Physiol Behav 44:327—332, 1988
8. WRIGHT 3W, MILLER-WING AV, SHAFFER Mi, HIGGIN50N C, WRIGHT
DE, HANESwORTH JM, HARDING JW: Angiotensin 11(3-8) [ANG IV]
hippocampal binding: Potential role in the facilitation of memory.
Brain Res Bull 32:497—502, 1993
9. BAKER 1CM, AcETO iF: Angiotensin II simulation of protein synthesis
and cell growth in chick heart cells. Am J Physiol 259:H610—H618,
1990
10. HARDING JW, COOK VI, MILLER-WING AV, HANE5wORTH JM, SAR-
DINIA MF, HAn. KL, STOBB 3W, SWANSON ON, Coww4 3K, WRIGHT
3W, HARDING EC: Identification of an MI (3-8) [MV] binding site in
guinea pig hippocampus. Brain Res 583:340—343, 1992
11. SWANSON ON, HANESWORTH 3M, SARDINIA MF, COLEMAN JK.,
WRIGHT JW, HALL KL, MILLER-WING AV, STosa 3W, COOK VI,
HARDING EC, HARDING 3W: Discovery of a distinct binding site for
angiotensin 11(3-8), a putative angiotensin for a receptor. Regul Pept
40:409—419, 1992
12. FLaL KL, HANESWORTH 3M, BALL AE, FELGENHANER GP, HosIcK
HL, HARDING 3W: Identification and characterization of a novel
angiotensin binding site in cultured vascular smooth muscle cells that
is specific for the hexapeptide (3-8) fragment of angiotensin II,
angiotensin IV. Regul Pept 44:225—232, 1993
13. HANESWORTH 3M, SARDINIA MF, KnEES LT, HALL KL, HARDING 3W:
Elucidation of a specific binding site for angiotensin 11(3-8), angio-
tensin IV, in mammalian heart membranes. J Pharmacol Exp Ther
266:1036—1042, 1993
14, MILLER-WING AV, HANESWORTH 3M, SARDINIA MF, WRIGHT 3W,
SPETH RC, GROVE KL, HARDING JW: Central angiotensin IV recep-
tors: Distribution and specificity in guinea pig brain. J Phannacol Exp
Ther (in press)
15. SARDIMA MF, HANESWORTH 3M, KnEES LT, HARDING 3W: AT4
receptor binding characteristics: D-amino acid- and glycine-substi-
tuted peptides. Peptides 14:949—954, 1993
16. LOWRY 0, RO5EEROUGH N, FARR A, RANaw. R: Protein measure-
ment with the Folin phenol reagent. J Biol Chem 193:265—275, 1951
17. Rowa BP, GROVE KL, SAYLOR DL, SPEm RC: Discrimination of
angiotensin II receptor subtype distribution in rat brain using non-
peptidic receptor antagonists. Regul Pept 33:45—53, 1991
